Company Overview - Yirui Technology has seen a stock price increase of 71.14% year-to-date, with a 3.53% rise in the last five trading days, 2.09% in the last 20 days, and 31.42% in the last 60 days [2] - The company specializes in the research, production, sales, and service of digital X-ray detectors, with its main revenue sources being detector sales (81.21%), core component sales (7.66%), solution/technical service income (5.89%), accessory sales (4.57%), and rental income (0.66%) [2] - As of June 30, 2025, Yirui Technology reported a revenue of 1.067 billion yuan, a year-on-year increase of 3.94%, and a net profit attributable to shareholders of 335 million yuan, up 8.82% year-on-year [2] Market Performance - As of September 30, Yirui Technology's stock price was 115.65 yuan per share, with a market capitalization of 23.155 billion yuan [1] - The trading volume was 1.03 billion yuan, with a turnover rate of 0.45% [1] - The net outflow of main funds was 1.8658 million yuan, with large orders accounting for 23.21% of purchases and 24.90% of sales [1] Shareholder Information - Yirui Technology has distributed a total of 789 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3] - As of June 30, 2025, the number of shareholders increased by 21.67% to 6,990, with an average of 28,643 circulating shares per person, up 15.02% [2][3] - The ninth largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 3.926 million shares as a new shareholder [3]

分红方面，春立医疗A股上市后累计派现3.59亿元。近三年，累计派现3.09亿元。 机构持仓方面，截止2025年6月30日，春立医疗十大流通股东中，平安低碳经济混合A（009878）位居 第四大流通股东，持股377.00万股，相比上期增加277.00万股。南方医药保健灵活配置混合A （000452）位居第九大流通股东，持股160.30万股，为新进股东。中庚小盘价值股票（007130）、香港 中央结算有限公司、中庚价值先锋股票（012930）退出十大流通股东之列。 责任编辑：小浪快报 9月30日，春立医疗盘中上涨2.06%，截至10:29，报24.22元/股，成交1818.57万元，换手率0.26%，总市 值92.90亿元。 春立医疗所属申万行业为：医药生物-医疗器械-医疗耗材。所属概念板块包括：H股、新材料、增持回 购、口腔医疗、3D打印等。 资金流向方面，主力资金净流出328.37万元，大单买入47.54万元，占比2.61%，卖出375.91万元，占比 20.67%。 截至6月30日，春立医疗股东户数5920.00，较上期减少17.57%；人均流通股48836股，较上期增加 341.41%。2025年1月-6 ...

来源：新浪证券-红岸工作室 9月29日，春立医疗跌1.25%，成交额4610.74万元，换手率0.68%，总市值91.02亿元。 异动分析 牙科医疗+医疗器械概念+3D打印+专精特新+京津冀一体化 1、国内领先的骨科医疗器械厂商，春立医疗主营业务系植入性骨科医疗器械的研发、生产与销售，包 括口腔金属和隐形正畸 口腔种植和修复。 公司拟设计多孔钽定制个体化牙种植体产品并完成生产转 换， 目前处于设计送检阶段。 2、公司是国内领先的骨科医疗器械厂商，主营业务系植入性骨科医疗器械的研发、生产与销售。公司 主要产品为关节假体产品及脊柱类植入产品，其中关节假体产品涵盖髋、膝、肩、肘四大人体关节，脊 柱类植入产品为脊柱内固定系统的全系列产品组合。 3、2023年年报，公司已引入多种不同工艺类型的 3D 打印设备，"定制个体化假体系列产品研发项 目"亦在推进中。公司 3D 打印设备主要包括 EBM（电子束熔融）设备、MJF（多射流熔融）设备、送 粉金属 3D 打印设备等。其中，电子束熔融金属 3D 打印机通过在真空中使用电子束，将钛合金粉末一 层一层地融化，生成致密的零件，可实现多孔材料的打印。公司产品有3D 打印膝关节截 ...

Company Overview - Aidi Te (Qinhuangdao) Technology Co., Ltd. is located in Qinhuangdao Economic and Technological Development Zone, Hebei Province, established on March 15, 2007, and listed on June 26, 2024 [2] - The company specializes in the research, production, and sales of zirconia ceramic blocks and other dental restoration materials, with main business revenue composition: dental restoration materials 73.74%, dental digital equipment 19.80%, and other products and services 6.46% [2] Stock Performance - As of September 24, Aidi Te's stock price increased by 2.01% to 44.68 CNY per share, with a trading volume of 20.96 million CNY and a turnover rate of 0.66%, resulting in a total market capitalization of 4.761 billion CNY [1] - Year-to-date, the stock price has risen by 8.88%, but it has decreased by 3.19% over the last five trading days and 6.25% over the last twenty days, while increasing by 9.78% over the last sixty days [2] Financial Performance - For the first half of 2025, Aidi Te achieved operating revenue of 486 million CNY, representing a year-on-year growth of 17.22%, and a net profit attributable to shareholders of 92.04 million CNY, with a year-on-year increase of 19.86% [2] - Cumulative cash dividends since the A-share listing amount to 49.476 million CNY [3] Shareholder Information - As of June 30, 2025, the number of shareholders reached 9,412, an increase of 17.12% from the previous period, with an average of 7,651 circulating shares per person, up by 223.12% [2] - Notable changes in institutional holdings include the exit of several funds from the top ten circulating shareholders, such as Huatai-PineBridge Value Selection Mixed Fund and Galaxy Medical Mixed A [3]

截至6月30日，春立医疗股东户数5920.00，较上期减少17.57%；人均流通股48836股，较上期增加 341.41%。2025年1月-6月，春立医疗实现营业收入4.88亿元，同比增长28.27%；归母净利润1.14亿元， 同比增长44.85%。 来源：新浪证券-红岸工作室 春立医疗今年以来股价涨87.83%，近5个交易日涨3.46%，近20日涨9.26%，近60日涨29.59%。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期1998年2月12日，上市日期2021年12月30日，公司主营业务涉及北京市春立正达医疗器械 股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中国公司。该公司主要产品 为关节假体产品及脊柱类植入产品。关节假体产品涵盖髋、膝、肩、肘四大人体关节。脊柱类植入产品 为脊柱内固定系统的全系列产品组合。该公司的产品出口至亚洲、南美洲、非洲、大洋洲及欧洲等多个 国家和地区。主营业务收入构成为：医疗器械产品99.89%，其他(补充)0.11%。 春立医疗所属申万行业为：医药生物-医疗器械-医疗耗材。所属概念板块包括：口 ...

Core Viewpoint - Guocera Materials has shown a mixed performance in stock price and financial metrics, with a notable increase in revenue but only modest growth in net profit, indicating potential areas for investment consideration and risk assessment [1][2]. Financial Performance - As of June 30, Guocera Materials reported a revenue of 2.154 billion yuan, representing a year-on-year growth of 10.29% [2]. - The net profit attributable to shareholders was 332 million yuan, reflecting a slight increase of 0.38% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 870 million yuan, with 398 million yuan distributed over the past three years [3]. Stock Market Activity - On September 22, Guocera Materials' stock price increased by 2.02%, reaching 22.72 yuan per share, with a trading volume of 229 million yuan and a turnover rate of 1.22% [1]. - The stock has appreciated by 34.91% year-to-date, but has seen a decline of 4.01% over the last five trading days [1]. - The company has a total market capitalization of 22.653 billion yuan [1]. Shareholder Structure - As of June 30, the number of shareholders increased to 48,200, a rise of 14.53% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 12.68% to 17,470 shares [2]. - The largest circulating shareholder is Hong Kong Central Clearing Limited, holding 55.921 million shares, a decrease of 1.4332 million shares from the previous period [3]. Business Segments - Guocera Materials' main business segments include catalytic materials (34.54%), other materials (24.77%), biomedical materials (24.18%), electronic materials (19.37%), and others [1]. - The company is categorized under the electronic chemical industry and is involved in various concept sectors such as lithium batteries and new materials [1].

Company Overview - Sanxiang New Materials Co., Ltd. is located at 292 Jiefang Street, Shouning County, Fujian Province, established on August 24, 1991, and listed on August 1, 2016. The company specializes in the research, production, and sales of zirconium-based and casting modification industrial new materials [1][2] - The main revenue composition includes zirconium series products (84.25%), casting modification new materials (11.16%), and other products (4.59%) [1] Stock Performance - As of September 19, the stock price of Sanxiang New Materials increased by 2.05%, reaching 28.93 CNY per share, with a total market capitalization of 12.246 billion CNY [1] - Year-to-date, the stock price has risen by 82.24%, with a recent decline of 2.33% over the last five trading days, a 6.05% increase over the last 20 days, and a 10.44% increase over the last 60 days [1] Financial Performance - For the first half of 2025, Sanxiang New Materials reported a revenue of 562 million CNY, a year-on-year decrease of 7.35%, and a net profit attributable to shareholders of 44.91 million CNY, down 28.45% year-on-year [2] - The company has distributed a total of 208 million CNY in dividends since its A-share listing, with 93.76 million CNY distributed over the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Sanxiang New Materials was 32,800, a decrease of 7.12% from the previous period, with an average of 12,892 circulating shares per shareholder, an increase of 7.67% [2] - The ninth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 1.798 million shares, an increase of 221,700 shares from the previous period [3] Market Activity - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on March 4, where it recorded a net buy of -4.4688 million CNY [1]

Company Overview - Dongfang Zirconium Industry Co., Ltd. is located in Shantou City, Guangdong Province, and was established on November 10, 1995. The company was listed on September 13, 2007. Its main business involves the research, development, production, and sales of zirconium series products [1][2]. Financial Performance - For the first half of 2025, Dongfang Zirconium achieved operating revenue of 626 million yuan, a year-on-year decrease of 23.07%. However, the net profit attributable to the parent company was 29.08 million yuan, reflecting a significant year-on-year increase of 148.58% [2]. - Since its A-share listing, the company has distributed a total of 30.11 million yuan in dividends, with no dividends paid in the last three years [3]. Stock Performance - As of September 19, the stock price of Dongfang Zirconium rose by 2.00% to 14.79 yuan per share, with a trading volume of 243 million yuan and a turnover rate of 2.19%. The total market capitalization is 11.457 billion yuan [1]. - Year-to-date, the stock price has increased by 101.50%, with a recent decline of 4.09% over the last five trading days, a 10.21% increase over the last 20 days, and a 33.73% increase over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 110,600, up by 10.25% from the previous period. The average number of circulating shares per shareholder decreased by 9.34% to 6,849 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the second-largest shareholder, holding 6.6647 million shares, a decrease of 3.0102 million shares compared to the previous period [3]. Market Position - Dongfang Zirconium is classified under the non-ferrous metals sector, specifically in the small metals category. The company is involved in various concept sectors, including solid-state batteries, lithium batteries, small metals, new materials, and dental medical products [2].

9月18日，奕瑞科技盘中下跌2.02%，截至13:46，报111.70元/股，成交2.48亿元，换手率1.09%，总市值 223.64亿元。 奕瑞科技所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：口腔医疗、专精特新、 融资融券、中盘、增持回购等。 截至6月30日，奕瑞科技股东户数6990.00，较上期增加21.67%；人均流通股28643股，较上期增加 15.02%。2025年1月-6月，奕瑞科技实现营业收入10.67亿元，同比增长3.94%；归母净利润3.35亿元，同 比增长8.82%。 分红方面，奕瑞科技A股上市后累计派现7.89亿元。近三年，累计派现5.57亿元。 机构持仓方面，截止2025年6月30日，奕瑞科技十大流通股东中，华宝中证医疗ETF（512170）位居第 九大流通股东，持股392.60万股，为新进股东。景顺长城新能源产业股票A类（011328）退出十大流通 股东之列。 责任编辑：小浪快报 资金流向方面，主力资金净流出679.79万元，特大单买入1264.27万元，占比5.10%，卖出3179.83万元， 占比12.83%；大单买入5865.77万元，占比23.67%，卖出 ...

Company Overview - Yirui Technology, established on March 7, 2011, and listed on September 18, 2020, is located in Shanghai and specializes in the research, production, sales, and service of digital X-ray detectors [1] - The company's main revenue sources include detector sales (81.21%), core component sales (7.66%), solution/technical service income (5.89%), accessory sales (4.57%), and rental income (0.66%) [1] Financial Performance - As of June 30, 2025, Yirui Technology reported a revenue of 1.067 billion yuan, representing a year-on-year growth of 3.94%, and a net profit attributable to shareholders of 335 million yuan, with an increase of 8.82% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 789 million yuan, with 557 million yuan distributed over the past three years [3] Stock Market Activity - On September 17, Yirui Technology's stock price decreased by 2.02%, trading at 112.33 yuan per share, with a total market capitalization of 22.491 billion yuan [1] - The stock has seen a year-to-date increase of 66.23%, with a 1.95% rise over the last five trading days, 1.98% over the last twenty days, and 24.88% over the last sixty days [1] - As of June 30, 2025, the number of shareholders increased by 21.67% to 6,990, with an average of 28,643 circulating shares per shareholder, up 15.02% [2] Institutional Holdings - As of June 30, 2025, the ninth largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 3.926 million shares as a new shareholder, while the Invesco Great Wall New Energy Industry Stock A Class has exited the top ten circulating shareholders [3]